Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
June 15, 2024 10:00 ET
|
F. Hoffmann-La Roche Ltd
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi...
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
June 10, 2024 01:05 ET
|
F. Hoffmann-La Roche Ltd
The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent...
European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
June 10, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease...
Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk
June 07, 2024 10:40 ET
|
F. Hoffmann-La Roche Ltd
After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age96% of Evrysdi-treated children could...
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 29, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an...
Wechsel in der erweiterten Konzernleitung von Roche
May 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27. Mai 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass James Sabry (1958), M.D. Ph.D. und Leiter von Roche Pharma Partnering, nach vierzehn Jahren bei Roche in den Ruhestand...
Changes to the Roche Enlarged Corporate Executive Committee
May 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry...
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
May 22, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 21, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
May 16, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100%...